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Selection of recently formed B cells into the follicular or marginal zone (MZ) compartments is 
proposed to occur by way of proliferative intermediates expressing high levels of CD21/35 and 
CD23. However, we show that CD21/35
 
high
 
 CD23
 
 
 
 splenocytes are not enriched for proliferative 
cells, and do not contribute substantially to the generation of follicular B cells. Instead, 
ontogenic relationships, steady-state labeling kinetics, and adoptive transfer experiments 
suggest that CD21/35
 
high
 
 CD23
 
 
 
 splenocytes serve primarily as precursors for MZ B cells, 
although their developmental potential seems to be broader and is influenced by environmental 
cues that are associated with lymphopenia. Furthermore, CD21/35
 
high
 
 CD23
 
 
 
 splenocytes 
share several key functional characteristics with MZ B cells, including their capacity to trap 
T-independent antigen and a heightened proliferative response to LPS. These observations 
challenge previous models of peripheral B cell maturation, and suggest that MZ B cells 
develop by way of CD21/35
 
high
 
 CD23
 
 
 
 intermediates.
 
In adults, B cells are generated from B-lineage
committed precursors in the BM. Newly
formed sIgM
 
 
 
 B cells in the BM are subjected
to multiple selective pressures that purge autore-
active B cells and guide differentiation of the
remaining cells into functionally distinct pe-
ripheral B cell compartments. Ultimately, imma-
ture B cells yield follicular or marginal zone
(MZ) B cells, mature subsets that differ in their
surface phenotype, anatomic localization, and
immunologic function (1).
Newly formed B cells are exported to pe-
ripheral lymphoid tissues as functionally imma-
ture, or transitional, intermediates (2–7). How-
ever, the classification of immature splenic B
cells and the resulting models of peripheral B
cell maturation are controversial. One classifica-
tion scheme put forth by Loder et al. (5) used
variable surface levels of CD21/35, CD23, and
IgD to divide CD24/HSA
 
high
 
 splenic B cells
into two subsets, termed T1 and T2. The T2
subset was postulated to contain precursors for
follicular and MZ B cells, and seemed to be
enriched for proliferative cells in vivo. An alter-
native classification from Allman et al. (6) used
the developmental marker AA4 and variable
surface levels of IgM and CD23 to delineate
three transitional populations, T1 through T3.
Allman et al. (6) found that the transitional
subsets were nonproliferative in vivo and unre-
sponsive to B cell receptor (BCR) cross-linking
ex vivo. Thus, the T2 stage described by Loder
et al. (5) may be distinct from the transitional
subsets described by Allman et al. (6). For clarity,
we refer to the T2 subset described by Loder et
al. as CD21/35
 
high
 
 CD23
 
 
 
 splenocytes.
Several studies question the requirement of
CD21/35
 
high
 
 CD23
 
 
 
 splenocytes as intermedi-
ates for follicular B cell development. Mice
deficient for the transcription factor Aiolos
lack MZ B cells and splenic B cells expressing
high levels of IgM, CD21/35, and IgD (likely
equivalent to CD21/35
 
high
 
 CD23
 
 
 
 splenocytes),
but have an enlarged pool of hyperactivated
follicular B cells (8, 9). Similarly, mice with a
conditional deletion of the transmembrane re-
ceptor Notch2 (10), or mice that are unable to
signal through the Notch pathway (11), lack
MZ B cells and CD21/35
 
high
 
 CD23
 
 
 
 spleno-
cytes, whereas their follicular pool appears nor-
mal in size and function. This genetic evidence
argues against classification of CD21/35
 
high
 
CD23
 
 
 
 splenocytes as intermediates in the de-
velopment of follicular B cells, and instead, sug-
gests a potential relationship with MZ B cells.
We sought to resolve controversies regarding
the classification of immature B cells and to
explore lineage relationships between immature
and mature B cell subsets. Accordingly, we in-
corporated lineage makers from diverse pheno-
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typing schemes, and applied kinetic studies to probe the cel-
lular dynamics and developmental relationships among each
relevant B cell subset. We find that CD21/35
 
high
 
 CD23
 
 
 
splenocytes are a nondividing cell population whose devel-
opmental kinetics and functional attributes are most consis-
tent with a direct precursor–product relationship between
CD21/35
 
high
 
 CD23
 
 
 
 splenocytes and MZ B cells.
 
RESULTS
CD21/35
 
high
 
 CD23
 
 
 
 splenocytes are distinguishable 
from most transitional B cells
 
Several approaches have been used to identify subsets of im-
mature and mature splenic B cells. Whereas most studies
agree on the phenotype of follicular (sIgM
 
int/low
 
 sIgD
 
high
 
CD23
 
 
 
 CD21/35
 
int
 
 AA4
 
 
 
) and MZ (sIgM
 
high
 
 sIgD
 
low
 
CD23
 
low
 
 CD21/35
 
high
 
 AA4
 
 
 
) B cells, the surface phenotype
of immature B cells is more controversial. Loder et al. (5)
defined two sets of transitional B cells, T1 and T2. In this
scheme, T1 splenocytes are sIgM
 
high
 
 sIgD
 
low
 
 CD23
 
low
 
CD21/35
 
low
 
, whereas T2 splenocytes are sIgM
 
high
 
 sIgD
 
high
 
CD23
 
 
 
 CD21/35
 
int/high
 
. An alternative scheme that was pro-
posed by Allman et al. (6) uses the differential surface expres-
sion of AA4 to delineate three AA4
 
 
 
 transitional pools,
termed T1 through T3. T1 splenocytes are sIgM
 
high
 
 CD23
 
 
 
,
T2 splenocytes are sIgM
 
high
 
 CD23
 
 
 
, and T3 splenocytes are
sIgM
 
low
 
 CD23
 
 
 
. Other studies on peripheral B cell subsets
have used combinations of sIgM and sIgD (9) or CD21/35,
sIgM, and CD23 (12) to identify immature and mature B
cell subsets.
We used seven-color flow cytometry to analyze simulta-
neously the surface markers that were used in each of these
previous studies. Fig. 1 A shows sIgM and CD21/35 levels
on B220
 
 
 
 splenocytes from an 8-wk-old C57BL/6 mouse.
Using initial gates similar to those of Martin and Kearney
(12), we defined three fractions (Frs. I–III). These three pop-
ulations were subdivided based on differential AA4 and
CD23 levels, and were given the designations shown in Fig.
1 A. Most cells in Fr. I are AA4
 
 
 
 and correspond to the bulk
of immature B cells in the adult spleen. The AA4
 
 
 
 CD23
 
 
 
population in Fr. I is T1 in the nomenclature of Allman et al.
(6) and Loder et al (5), and the AA4
 
 
 
 CD23
 
 
 
 population is
T2 in the nomenclature of Allman et al. Notably, the T2
population defined in this manner includes the CD21/35
 
int
 
fraction of the T2 population as originally defined by Loder
et al. (5). The AA4
 
 
 
 CD23
 
 
 
 sIgM
 
high
 
 population of Fr. I
corresponds to a recently characterized subset of recirculat-
ing cells whose development is independent of the Tec-fam-
ily tyrosine kinase, Btk (13). Fr. II includes a minor popula-
tion of AA4
 
 
 
 CD23
 
 
 
 cells—T3 in the nomenclature of
Allman et al.—whereas the bulk of Fr. II cells are AA4
 
 
 
 fol-
Figure 1. Resolution of splenic B cell subsets. (A) Splenocytes from an 
8-wk-old C57BL/6 mouse were harvested and stained with sIgM-FITC, 
CD23-PE, CD21/35-PECy5.5, B220-APCCy7, AA4-APC, and sIgD-biotin 
revealed with SA-PECy7. (Top row) sIgM and CD21/35 levels on FSC- and 
SSC-gated DAPI  B220  lymphocytes. (Bottom row) CD23 and AA4 levels 
on the three fractions defined above. (B) sIgD levels on six populations 
defined in (A). (C) Cells from spleen or BM were stained for surface markers 
as in 1, A and B, fixed, permeabilized, and stained with DAPI. Line graphs 
show DAPI profiles on the seven splenic populations and two BM populations 
(gated as described in the text) for positive and negative controls. Gates 
show the fraction of cells in G2/M, with average percentages and standard 
deviations derived from three separate mice shown above the gate. 
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licular B cells. Approximately one third of the cells within
Fr. III are CD23
 
 
 
 cells that correspond to the CD21/35
 
high
 
fraction of the Loder et al. (5) T2 subset; the remainder of
Fr. III contains CD23
 
low
 
 MZ B cells. Many CD21/35
 
high
 
CD23
 
 
 
 splenocytes are AA4
 
low
 
, which suggests that these
cells include recent emigrants from the BM, but constitute a
more mature subset than the uniformly AA4
 
 
 
 T1 and T2
subsets. Relative levels of sIgD are illustrated in Fig. 1 B. As
reported previously (6), sIgD levels increase as cells mature
from T1 to T2 and are high on T3 and follicular B cells. As
reported by Loder et al. (5), sIgD levels are high on CD21/
35
 
high
 
 CD23
 
 
 
 splenocytes but are lower on MZ B cells.
Thus, this flow cytometric scheme allows for clear resolution
of seven subpopulations of adult splenic B cells, and directly
shows that AA4
 
 
 
 CD23
 
 
 
 CD21/35
 
low
 
 “T2” transitional B
cells are distinct from the CD21/35
 
high
 
 CD23
 
 
 
 splenic B cell
subset that was described by Loder et al.
 
AA4
 
low
 
 CD21/35
 
high
 
 CD23
 
 
 
 splenocytes are nonproliferative 
in vivo
 
Previous analyses reported that 
 
 
 
15% of CD21/35
 
high
 
CD23
 
 
 
 splenocytes are contained within the G
 
2
 
/M phase
of the cell cycle (5). This observation, combined with other
studies that suggested that these splenocytes proliferate, up-
regulate survival pathways, and differentiate into follicular
B cells upon BCR cross-linking (14, 15), supports the ex-
istence of a BCR-mediated proliferative burst that is associ-
ated with the selection and expansion of useful clones
Figure 2. Reconstitution of splenic B cell subsets. Chimeras were 
generated by reconstituting irradiated C57BL/6 (Ly5B6) hosts with congenic 
B6.Ly5.2 (Ly5SJL) B220-depleted BM. The composition of the peripheral B cell 
pool was assessed daily starting on day 12 using the markers in Figure 1 
(except IgD) and incorporating congenic markers. (A) CD21/35 and sIgM 
levels on donor-gated DAPI  B220  cells on the indicated days. (B) CD23 
and AA4 levels on the three gated fractions shown in A. (C) Absolute cells 
numbers for each population at the indicated time points. 
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among late transitional B cells. However, several studies
that evaluated in vivo BrdU incorporation rates failed to
observe rapid accumulation of BrdU
 
 
 
 mature B cells as
predicted (3, 6, 7). Accordingly, we directly examined cell
cycle profiles for the splenic B cell subsets that are illus-
trated in Fig. 1 A. For these analyses, cellular doublets were
excluded from postdata collection analyses (see Materials
and methods). As shown in Fig. 1 C, as expected, 
 
 
 
36%
and 
 
 
 
3%
 
 
 
of BM large pre–B II cells (B220
 
 
 
 CD25
 
 
 
FSC
 
high
 
) and small pre–B II cells (B220
 
 
 
 CD25
 
 
 
 FSC
 
low
 
),
respectively, were contained within the G
 
2
 
/M phase of the
cell cycle (16). However, none of the splenic B cell subsets
that were defined in Fig. 1 A, including the CD21/35
 
high
 
CD23
 
 
 
 subpopulation, was enriched for cells in the S or
G
 
2
 
/M phases of the cell cycle (Fig. 1 C). We conclude that
CD21/35
 
high
 
 CD23
 
 
 
 splenocytes are not enriched for pro-
liferative cells in vivo.
 
Developmental kinetics of CD21/35
 
high
 
 CD23
 
 
 
 splenocytes
 
Given the genetic data that implicate CD21/35
 
high
 
 CD23
 
 
 
splenocytes in the generation of MZ B cells (9, 10), we
sought to determine developmental relationships for these
populations using two complementary approaches. First, we
conducted reconstitution experiments in which congenic,
B220-depleted B6.Ly5SJL BM was transferred into irradiated
C57BL/6 (Ly5B6) hosts, and the composition of the donor-
derived peripheral B cell pool was assessed each day follow-
ing reconstitution, beginning on day 15. Second, we used
continuous in vivo BrdU labeling to assess steady-state turn-
over and production rates in 8-wk-old C57BL/6 mice.
Fig. 2 illustrates donor-derived B cells (B220  Ly5SJL )
in host spleens on the indicated days after reconstitution. As
expected, at early time points, reconstitution was restricted
to Fr. I, with the T1 and T2 AA4  populations evident at
this time. In addition, the very few cells detected in Fr. II on
day 15 were restricted to the AA4  T3 pool. Initial reconsti-
tution of the follicular pool was evidenced first on day 17.
By analyzing 200,000 cells per sample, we were able to de-
tect small numbers of AA4low CD21/35high CD23  cells and
MZ B cells at this time (Fig. 2 B, day 17). These data are
consistent with the reported delayed emergence of MZ B
cells (17). Furthermore, reconstitution of the CD21/35high
CD23  pool slightly preceded reconstitution of the MZ B
pool, as judged by the early predominance of CD21/35high
CD23  cells when compared with MZ B cells (Fig. 2 B,
panel with asterisk). Thus, CD21/35high CD23  cells
emerged well after AA4  transitional populations T1
through T3, and slightly before MZ B cells. Fig. 2 C illus-
trates the absolute number of cells in each population as a
function of time. Significant numbers of AA4  transitional
and follicular B cells were noted readily before detection of
the CD21/35high CD23  subset, which shows that most
CD21/35high CD23  splenocytes arose well after initial re-
constitution of follicular B cells. These data argue against
classification of CD21/35high CD23  splenocytes as precur-
sors in follicular B cell development, and instead, suggest a
close developmental relationship between AA4low sIgMhigh
CD21/35high CD23  splenocytes and MZ B cells.
BrdU-labeling kinetics
To evaluate further the lineage relationships suggested by
Fig. 2, we examined the steady-state cellular dynamics of
each subset illustrated in Fig. 1 by way of continuous in vivo
BrdU labeling. Cohorts of 8-wk-old C57BL/6 adults were
inoculated i.p. with BrdU every 12 h, and BrdU incorpora-
tion was assessed at 2, 4, or 6 days. As reported previously
(6), the AA4  transitional population T2 labeled rapidly,
with  60% labeling by day 4. In contrast, follicular B cells,
CD21/35high CD23  splenocytes, and MZ B cells all labeled
relatively slowly, with 5%, 10%, and 15% labeling on day 4,
respectively (Fig. 3 A). We further estimated production
rates for each pool. The number of CD21/35high CD23  B
cells produced per day was markedly insufficient to sustain
the follicular B cell pool. Whereas 3.8   105 follicular B cells
were produced per day, only 0.4   105 CD21/35high
CD23  B cells were generated per day (Fig. 3 B). Signifi-
cantly, CD21/35high CD23  splenocytes exhibited slightly
accelerated labeling kinetics relative to MZ B cells (Fig. 3 A),
and production rates for CD21/35high CD23  B cells mir-
rored those for MZ B cells (Fig. 3 B). These data, together
with the reconstitution data in Fig. 2, suggest a direct pre-
Figure 3. BrdU labeling of peripheral B cell pools. 8-wk-old C57BL/6 
mice (three mice per time point) were inoculated i.p. with BrdU every 12 h 
for 2, 4, or 6 d. Mice were killed, and splenocytes were stained with the 
surface markers in Fig. 1 (excluding IgD), and then stained intracellularly 
for BrdU incorporation as described in Materials and methods. (A) Percent 
labeling within the T2, follicular B cell (FoB), CD21/35high CD23 , and 
marginal zone B (MZB) cell pools as a function of time. (B) Number of cells 
generated in those pools per day estimated by calculating the average 
number of BrdU  cells generated each day between days 2 and 4.JEM VOL. 202, November 7, 2005 1229
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cursor–product relationship for CD21/35high CD23  and
MZ B cells.
CD21/35high CD23  splenocytes are intermediates 
in the development of MZ B cells
Next, we conducted several adoptive transfer experiments to
assess directly whether CD21/35high CD23  splenocytes are
MZ B cell precursors. We sorted and transferred 250,000
CD21/35high CD23  splenocytes from B6.Ly5SJL donors into
C57BL/6 or RAG2 /  (both Ly5B6 ) hosts. 4.5 d after
transfer, we assessed the phenotype of donor B cells by gat-
ing on B220  Ly5B6  splenocytes. As seen in Fig. 4 A,
CD21/35high CD23  splenocytes efficiently gave rise to
CD21/35high IgMhigh CD23low CD1dhigh MZ B cells in
RAG2 /  hosts, but seemed to lose some  CD21/35 and
sIgM expression while maintaining CD23 and sIgD expres-
sion in C57BL/6 hosts. Consistent with previous data (18),
recoveries in both host types typically were 1–2% (unpub-
lished data). We conclude that CD21/35high CD23  spleno-
cytes can give rise to MZ B cells in lymphopenic hosts but
seem to give rise to follicular B cells in replete hosts; this
suggests that competitive pressures may influence peripheral
B cell fate.
Because AA4  T2 B cells are considered late-stage im-
mature B cells, we reasoned that these cells should give rise
to MZ B cells and follicular B cells upon adoptive transfer.
Furthermore, if the CD21/35high CD23  population is an
intermediate in MZ B cell development, the AA4  T2 sple-
nocytes might pass through this stage as they differentiate
into MZ B cells. Accordingly, we sorted and transferred
250,000 AA4  T2 cells from B6.Ly5SJL donors into C57BL/6
or RAG2 /  hosts. The donor inoculum for AA4  T2 sple-
nocytes contained only 0.1–0.2% contamination by MZ
B cells (unpublished data). Given a 1–2% homing efficiency,
this implies that virtually no MZ B cells would be transferred
to the host. As shown in Fig. 4 B, AA4  T2 splenocytes effi-
ciently gave rise to MZ B cells in RAG2 /  hosts at day 4,
but gave rise to CD21/35int IgMint/lo CD23  CD1dlow follic-
ular B cells in C57BL/6 hosts. Importantly, at day 2.5 after
transfer, the AA4  T2 splenocytes in RAG2 /  hosts ex-
pressed high levels of CD21/35 and sIgM, and maintained
high expression of CD23 and sIgD (Fig. 2 B, first row).
Thus, AA4  T2 splenocytes transit through a CD21/35high
CD23  stage en route to the MZ B stage.
Because the host environment influenced whether recov-
ered AA4  T2 cells exhibited a follicular or MZ B cell surface
phenotype (Fig. 4 B), we further reasoned that mature follic-
ular B cells also might yield MZ B cells when transferred into
B cell–deficient, but not B cell–sufficient, hosts. Previous
studies that employed transfer of unfractionated B cells from
the mouse lymph node or rat thoracic duct suggested that
mature B cells generate MZ-like B cells upon transfer into
lymphopenic hosts (19, 20). However, these MZ-like cells
also may derive from late transitional B cells, which are
readily detectable in the lymph node and among recirculating
B cells in the peripheral blood (unpublished data). Accord-
ingly, we determined whether highly purified splenic follicu-
lar B cells, as defined in Fig. 1, yielded MZ B cells when
transferred into RAG2 /  hosts, and whether such differenti-
ation was accompanied by the initial acquisition of a sIgMhigh
CD21/35high CD23  surface phenotype. As shown in Fig. 4
C, at day 2.5 after transfer, donor B cells that were recovered
from RAG2 /  hosts were CD21/35high CD23  sIgMhigh. By
day 4.5, a subset of the donor B cells had down-regulated
CD23, and by day 8.5, donor B cells also were sIgDlow, which
indicated further differentiation along the MZ B cell pathway
(Fig. 4 C). In contrast, at day 2.5 and all subsequent time
points, donor B cells that were recovered from C57BL/6
hosts retained a sIgMlow CD21/35low CD23  surface pheno-
type that is typical of follicular B cells. We also conducted im-
munohistochemical and functional analyses to test whether
Figure 4. Adoptive transfer of peripheral B cell subsets. Cells were 
sorted from splenocytes of B6.Ly5SJL mice using the surface markers in Fig. 1 
(excluding IgD), and then transferred into C57BL/6 or C57BL/6-back-
crossed RAG2 /  (both Ly5B6 ) hosts. Host splenocytes were harvested at 
the indicated time points, and were stained with the indicated antibodies, 
including anti-Ly5B6 antibodies. Line graphs show overlays of surface 
markers on donor B cells (identified as Ly5B6  B220 ): red, donor cells in 
RAG2 /  hosts; black, donor cells in C57BL/6 hosts; gray, host splenic B 
cells (Ly5B6  B220 ). (A) Phenotype of CD21/35high CD23  splenocytes at 
day 4.5 after transfer. (B) Phenotype of AA4  T2 splenocytes at days 2.5 
and 4 after transfer. (C) Phenotype of follicular B cells at days 2.5, 4.5, and 
8.5 after transfer.MARGINAL ZONE B CELL PRECURSORS | Srivastava et al. 1230
transferred follicular B cells localized to the MZ and acquired
attributes that are characteristic of MZ B cells (unpublished
data). Transferred follicular B cells colocalized with MOMA 
metallophillic macrophages in the splenic MZ (21), and ac-
quired the capacity to trap T-independent antigens (22, 23)
and stimulate allogeneic CD4  T cells in a mixed lymphocyte
reaction (24). Again, cell recoveries for all follicular B cell
transfers typically were 1–2% of the donor inoculum, but sort
purities for follicular B cells typically were  99%, with
 0.1% contamination by MZ B cells (unpublished data).
These high sort purities, the stepwise differentiation of AA4 
T2 and follicular B cells in RAG2 /  hosts, and the mainte-
nance of the follicular phenotype in C57BL/6 hosts argue
that selective survival of contaminating MZ B cells is unlikely
to account for these data. Overall, these results strengthen the
notion that CD21/35high CD23  splenocytes are an interme-
diate in the differentiation pathway of MZ B cells.
CD21/35high CD23  splenocytes share key characteristics 
with MZ B cells
If CD21/35high CD23  splenocytes are immediate precursors
for MZ B cells, they might share certain functional charac-
teristics with them. One functional characteristic of MZ B
cells is their ability to trap the T-independent antigen TNP-
Ficoll (22, 23). To assess whether CD21/35high CD23  sple-
nocytes share this characteristic with MZ B cells, we injected
C57BL/6 mice i.v. with TNP-Ficoll or PBS. 30 min later,
each splenic B cell subset was examined for antigen reten-
tion. As shown in Fig. 5 A, follicular B cells and AA4  T2
cells trapped relatively little TNP-Ficoll, whereas MZ and
CD21/35high CD23  B cells trapped a relatively large
amount of TNP-Ficoll on their surfaces. Thus, CD21/35high
CD23  splenocytes mirror MZ B cells with regard to their
capacity to trap T-independent antigens.
MZ B cells also express higher levels of the integrins  L 2
and  4 7 than do follicular B cells. Binding of these integrins
to their ligands, intercellular adhesion molecule and vascular
cell adhesion molecule (VCAM), respectively, is critical for
retention of MZ B cells in their anatomic niche (25). Surface
expression of these integrins on AA4  T2 cells, follicular B
cells, CD21/35high CD23  splenocytes, and MZ B cells are
shown in Fig. 5 B. MZ and CD21/35high CD23  B cells ex-
hibit elevated levels of  L 2, whereas AA4  T2 cells express
lower levels, similar to follicular B cells. In contrast,  4 7 is
expressed at low levels on follicular B cells, at intermediate
levels on T2 and CD21/35high CD23  B cells, and at high
levels on MZ B cells (25). Thus, CD21/35high CD23  spleno-
cytes may exhibit enhanced binding to intercellular adhesion
molecule, but not to VCAM. We also assayed the expression
of markers that were reported to differ on MZ B cells and fol-
licular B cells. The glycolipid presentation molecule, CD1d, is
expressed at higher level on MZ B cells (26) and, in line with
previous findings (27), has intermediate expression on CD21/
35high CD23  splenocytes relative to AA4  T2 and follicular
B cells. In addition, the adhesion molecule CD9 is expressed
preferentially on MZ B cells (28) and shows intermediate lev-
els on CD21/35high CD23  splenocytes. Finally, expression of
the Toll-like receptor homologue RP105 was expressed at
roughly equivalent levels on MZ and CD21/35high CD23 
splenocytes, and was significantly higher on these cells com-
pared with follicular and AA4  T2 B cells.
Finally, we assessed whether CD21/35high CD23  sple-
nocytes exhibit robust proliferation to LPS, which is charac-
teristic of MZ B cells (29). Fig. 6 A shows the proliferation
profiles of sorted, carboxyl fluorescein succinimidyl ester
(CFSE)–labeled follicular, CD21/35high CD23  and MZ B
cells that were stimulated by BCR cross-linking or LPS. Fig.
6 B shows the responder frequencies and proliferative capac-
ities that were calculated from these CFSE profiles (30). Like
MZ B cells, CD21/35high CD23  splenocytes show a much
stronger response to LPS than do follicular B cells. This
greater response is reflected in a larger responder frequency,
rather than a greater proliferative capacity. Strikingly, CD21/
35high CD23  splenocytes also responded robustly to BCR
cross-linking, which distinguishes them from MZ B cells and
from AA4  transitional cells, which are nonproliferative to
BCR cross-linking (6, 29). Thus, CD21/35high CD23  sple-
nocytes share many characteristics with MZ B cells, but are
not functionally equivalent to MZ B cells. Overall, these
Figure 5. Trapping of T-independent antigen and integrin expression. 
(A) C57BL/6 mice were injected with 500  g of TNP-Ficoll in PBS or PBS 
alone. 30 min later, splenocytes were stained with the surface markers in 
Fig. 1 (except IgD) and biotinylated anti-TNP-Ficoll (revealed with SA-PECy7). 
The levels of bound TNP-Ficoll are shown as line graph overlays; red and 
blue lines show signals from PBS-injected and TNP-Ficoll injected mice, 
respectively. (B) Expression of MZ-specific surface markers, including 
integrins, CD1d, CD9, and RP105, on T2, follicular B cell (FoB), CD21/35high 
CD23 , and MZ B cells. Surface levels are shown as line graph overlays.JEM VOL. 202, November 7, 2005 1231
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similarities strengthen the idea that CD21/35high CD23 
splenocytes have initiated the developmental program that
distinguishes MZ B cells from other splenic B cells.
DISCUSSION
Nonfollicular CD23  splenic B cells can be divided into at
least two subsets (Fig. 1 A): a CD21/35int subset that ex-
presses relatively high levels of AA4, and a CD21/35high sub-
set that expresses low to background levels of AA4. The
former AA4  CD21/35int subset corresponds to the T2 pop-
ulation of Allman et al. (6) and includes a fraction of the T2
population of Loder et al. (5), whereas the latter AA4low
CD21/35high subset corresponds to a fraction of the T2 pop-
ulation that was defined by Loder et al. (5). This population,
which we have referred to as CD21/35high CD23  spleno-
cytes, has many characteristics that distinguish it from the
bulk of immature cells and strongly implicate it as a precur-
sor pool for MZ B cells. During the early establishment of
the B cell pool, development of this subset is delayed com-
pared with the AA4  pools, T1 and T2; it coincides with the
development of follicular B cells; and it immediately pre-
cedes initial reconstitution of the MZ B cell pool (Fig. 2).
Moreover, BrdU labeling in adults indicates that the CD21/
35high CD23  splenocytes turn over relatively slowly, and are
generated in small numbers that are sufficient to account for
MZ B cell, but not for follicular B cell, production (Fig. 3).
Adoptive transfer experiments indicate that CD21/35high
CD23  splenocytes are an intermediate in the development
of MZ B cells from AA4  T2 splenocytes or follicular B cells
(Fig. 4) in RAG2 /  hosts. Taken together, ontogenic rela-
tionships, population dynamics, and lineage potentials that
were revealed by adoptive transfer argue against the classifi-
cation of CD21/35high CD23  splenocytes as significant in-
termediates in the development of follicular B cells, and sup-
port a precursor–product relationship with MZ B cells.
Several groups have investigated the characteristics of
CD21/35high CD23  splenocytes and have interpreted their
findings in the context of follicular B cell development.
However, our data suggest that many of the characteristics
that are attributed to late transitional B cells in these studies
may reflect events that are associated with MZ, rather than
follicular B cell, development. For instance, the reported up-
regulation of survival molecules among CD21/35high CD23 
splenocytes in response to BCR signaling that was observed
by Su and Rawlings (14) and Petro et al. (15), may reflect
BCR-mediated selection events that are associated with pro-
longed survival of MZ B cells, which unlike follicular B
cells, persist after cessation of B cell production in the BM
(31). Likewise, the exquisite sensitivity of CD21/35high
CD23  splenocytes to levels of the prosurvival cytokine,
BLyS (32, 33), most likely reflects a more stringent require-
ment for BLyS in the development and maintenance of MZ
cells and their precursors as compared with follicular B cells.
Similarly, many discrepancies in the literature can be clarified
by interpreting the CD21/35high CD23  splenocyte as a MZ
B cell precursor. In certain lymphopenic mice, such as IL-
7R  /  and xid mice, MZ B cells and CD21/35high CD23 
splenocytes are maintained, whereas AA4  transitional and
Figure 6. Mitogen responsiveness of purified splenic B cell 
subsets. Response of sorted CFSE-labeled follicular (FoB), CD21/35high 
CD23 , and MZ B cells to LPS (5  g/ml) or BCR-cross-linking (10  g/ml 
F[ab ]2 anti-IgM). (A) Plots show resulting CFSE levels on live (DAPI ) 
B220  cells at day 3 of culture with unstimulated cells in the gray filled 
line graphs. (B) Responder frequencies and proliferative capacities 
calculated from the plots in A by the method of Wells et al. (30). ND, no 
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follicular B cells are diminished severely (1, 34; and unpub-
lished data). Likewise, overexpression of the c-fos proto-
oncogene results in enhanced frequencies of MZ B cells as
well as CD21/35high CD23  splenocytes, whereas the num-
ber of earlier transitional cells and follicular B cells is un-
changed (35). Conversely, mice with a targeted disruption of
the G protein   inhibitory subunit exhibit decreased MZ
and CD21/35high CD23  B cell pools, and have increased
numbers of follicular B cells (36). These results are consistent
with our proposed precursor–product relationship, and sup-
port coordinate maintenance or expansion of MZ B cells and
their direct precursors.
Although CD21/35high CD23  splenocytes share several
characteristics with MZ B cells, these cells are not merely a
subset of MZ B cells, because CD21/35high CD23  spleno-
cytes do not seem to be functionally equivalent to MZ B
cells. First, CD21/35high CD23  splenocytes do not express
high levels of the integrin  4 7 (Fig. 4 A), which binds to
VCAM and is required to maintain MZ B cells in their ana-
tomic niche (25). This difference in integrin expression may
contribute to the localization of CD21/35high CD23  sple-
nocytes to the follicle, rather than the MZ (5, 37). Second,
CD21/35high CD23  splenocytes respond robustly to stimu-
lation by BCR cross-linking and LPS treatment, whereas
MZ B cells are unresponsive to stimulation through the
BCR but are robustly responsive to LPS (15, 38). The en-
hanced frequencies of LPS-responsive cells in the MZ and
CD21/35high CD23  pools correlated with increased surface
levels of the toll-like receptor homologue, RP105, a com-
ponent of the RP105/MD-1 complex that is associated with
LPS responsiveness (39). Thus, it is tempting to speculate
that LPS responsiveness for all splenic B cells—regardless of
their subset designation—may relate directly to surface den-
sities of RP105 on individual cells within each population.
Third, unlike MZ B cells, the development of CD21/35high
CD23  splenocytes seems to be independent of CD19, be-
cause CD19cre/cre mice lack MZ B cells (40), but contain
normal frequencies of CD21/35high CD23  splenocytes (un-
published data). The characteristics of MZ B cells and
CD21/35high CD23  splenocytes indicate functional distinc-
tions between these cells, and support a paradigm where de-
velopmental cues that act on the CD23  CD21/35high popu-
lation initiate or complete full differentiation of MZ B cells.
It is possible that a small fraction of follicular B cells de-
rive from CD21/35high CD23  splenocytes during steady-
state B cell development. When transferred into lympho-
sufficient hosts, CD21/35high CD23  splenocytes give rise to
cells with a follicular surface phenotype, although their sIgM
and CD21/35 levels are, on average, greater than those of
follicular B cells (Fig. 4 A). Whereas this result suggests a de-
gree of plasticity among CD21/35high CD23  splenocytes, it
is difficult to ascertain clear precursor–product relationships
from these experiments, which typically are characterized by
poor donor cell survival that likely is due to the failure of
donor cells to compete effectively with host cells for critical
microenvironmental niches. Neither the AA4  T2 (Fig. 4 B)
nor T1 subsets (not depicted) yielded MZ B cells upon
adoptive transfer into lympho-sufficient hosts, which sug-
gested that all donor cells failed to gain access to limiting fac-
tors that are required uniquely for MZ B cell differentiation.
Although the nature of these factors is not entirely clear,
they likely include the Notch2 ligand Delta-Like-1 (41), and
the antiapoptotic cytokine BLyS (32, 33). Likewise, because
each population tested gave rise to MZ-like B cells when
transferred into RAG2 /  hosts, we further suggest that re-
sources that are required for MZ B cell generation are avail-
able more readily in lymphopenic environments, which can
promote development of MZ B cells from multiple precur-
sor populations (Fig. 4).
Given our data, together with genetic data from the Aio-
los- and Notch-deficient mice (9–11), we propose that
CD21/35high CD23  splenocytes be termed marginal zone B
cell precursors. A similar suggestion was made recently by Pil-
lai et al. (42). We further propose a model of peripheral B cell
development, in which AA4  T2 splenocytes are the com-
mon precursor of follicular and MZ B cells and CD21/35high
CD23  splenocytes are the immediate precursor of MZ B
cells (Fig. 7). In addition to clarifying developmental relation-
ships among splenic B cells, clear resolution of MZ B cell pre-
cursors will allow better characterization of the requirements
for MZ versus follicular B cell development. Studies which
compare the gene expression profiles of AA4  transitional
populations, versus CD21/35high CD23  and MZ B cells,
should be especially useful in defining the molecular require-
ments that signal MZ B cell development.
MATERIALS AND METHODS
Mice. 6–10-wk-old C57BL/6 (Ly5B6), congenic B6.Ly5SJL (often termed
B6.Ly5.2), and RAG2 / mice were obtained from Jackson ImmunoRe-
search Laboratories or the National Cancer Institute. All live animal experi-
ments were performed according to protocols that were approved by the
Office of Regulatory Affairs of the University of Pennsylvania in accor-
dance with guidelines set forth by the National Institutes of Health.
Figure 7. Model for peripheral B cell maturation. The first cells to 
colonize the spleen are the AA4  T1 subset, which yields the AA4  T2 
subset that represents the common precursor of follicular and MZ B cells. 
CD21high CD23  splenocytes are the immediate precursor of MZ B cells, 
and might arise from AA4  T2 cells, follicular B cells, or both. It also is 
possible that CD21high CD23  splenocytes make a small contribution to the 
follicular pool, or that this subset is in dynamic equilibrium with the follicular 
subset. The relative thickness of the arrow represents the estimated flux 
from one compartment to another based on BrdU-labeling kinetics.JEM VOL. 202, November 7, 2005 1233
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Antibodies. Antibodies were purified and labeled in our laboratory or
purchased from the indicated vendor. Fluorescein-labeled antibodies in-
cluded monoclonal anti-B220 (RA3-6B2) and polyclonal Fab fragments of
goat anti–mouse IgM ( -chain specific, Jackson ImmunoResearch Labora-
tories). PE-labeled antibodies included AA4 (AA4.1), CD23 (B3B4, BD
Biosciences), IgD (11–26, Southern Biotechnology Associates, Inc.), heat
stable antigen (30F1), CD43 (S7), and anti-Ly5SJL (A20, BD Biosciences).
Biotin (BI)-conjugated antibodies included anti-Ly5SJL (BD Biosciences),
anti-Ly5B6 (104, BD Biosciences), CD1d (1B1, BD Biosciences), CD23
(BD Biosciences), and B220. PE-Cy5.5-anti-IgM (331.12), CD21/35
(7G6), and APC-conjugated anti-CD21/35, IgM (331.12), AA4, and B220
were prepared with standard methods in our laboratory. PE-Cy5.5 anti-
Ly5B6 (104), PE-Cy7 anti-Ly5SJL (A20)  and B220, and APC-Cy7 B220
were purchased from eBioscience. All BI-conjugated antibodies specific for
integrin family members were purchased from BD Biosciences. Streptavidin
(SA)-conjugated reagents included SA-PE-TexasRed (Caltag), and SA-
PE-Cy5.5 and SA-PE-Cy7 (eBioscience).
Cell preparation and staining. BM cells were flushed from tibias and fe-
murs, and splenocytes were prepared through perfusion of spleens with
FACS buffer (PBS containing 0.5% BSA 1 mM EDTA and 0.05% sodium
azide). After lysis of RBCs with ACT (BioWhittaker), 106 cells were washed
and then incubated with optimized dilutions of antibodies in 96-well
round-bottom plates in a final volume of 50  l. After 30 min on ice, plates
were washed twice with FACS buffer then, when appropriate, cells were
incubated for 20 min on ice with an optimal dilution of fluorochrome-con-
jugated SA in 25–40  l, then washed and resuspended in FACS buffer.
Flow cytometry and cell sorting. Analyses were performed on a dual-
laser flow cytometer (FACSCalibur, Becton Dickinson), a four-laser 10-
color LSR II (Becton Dickinson), or a three-laser 8-color MoFlo cell sorter
(DakoCytomation). All flow cytometry data were analyzed by uploading
files into FlowJo 4.6 (TreeStar, Inc.). Data collected on the LSR II or MoFlo
sometimes were subjected to the data transformation algorithm in FlowJo
that allows negative cell populations to be viewed as symmetric clusters.
Cells were sorted on a MoFlo cell sorter; cell suspensions were applied at a
sheath pressure of 60 psi, and a drop delay frequency of  98,000 drops/s.
This resulted in sorting rates of 28–30,000 cells/s with abort rates of 10–12%.
In vivo cell cycle analysis. To determine the degree of proliferation in
vivo, splenocytes were surface stained as described above, washed in PBS,
then fixed and permeabilized using the Fix & Perm kit from Caltag. Cells
were washed twice and resuspended in 1 ml PBS before addition of DAPI
at a final concentration of 10  g/ml. Cells were incubated for  30 min at
room temperature before analysis on the LSR II using a violet (405 nm) la-
ser for DAPI excitation. Doublets were excluded by gating on the area and
width parameters of the DAPI signal.
Adoptive transfers. B cell subsets were sorted into RPMI plus 5% FBS
according to the gating strategies shown in Fig. 1, washed in PBS, and re-
suspended in 400  l PBS per recipient before adoptive transfer by way of
the retro-orbital sinus.
BrdU incorporation. Continuous in vivo BrdU labeling was performed as
described previously (6) with the addition of the appropriately conjugated an-
tibodies. In brief, adult C57BL/6 mice were inoculated i.p. with 0.5 mg
BrdU (Sigma-Aldrich) in PBS every 12 h for up to 8 d. BM and spleen cells
were stained with PE-CD23, PE-Cy5.5 CD21/35, PE-Cy7 B220, APC-Cy7
anti-IgM (331), and APC-AA4.1 in standard FACS buffer, washed twice
with protein-free PBS, then permeabilized using “Fix and Perm” (Caltag).
Cells were washed, incubated with DNaseI, washed, and stained with fluores-
cein–anti-BrdU (Becton Dickinson) before analysis on an LSR II.
TNP-Ficoll binding assay. Mice were inoculated by way of the retro-
orbital sinus with 500  l of 1 mg/ml TNP-Ficoll (Biosearch Technologies)
suspended in PBS, and were killed 30 min later. Splenocytes were prepared
and stained as in Fig. 1 with inclusion of BI-conjugated anti-TNP-Ficoll
(BD Biosciences) revealed with SA-PE Cy7.
Stimulation of sorted B cells. Sorted B cells were CFSE-labeled with a
2-min incubation in 5  M CFSE diluted in PBS, and washed and plated at
20,000 cells/well in media (RPMI 1640, 10% FBS [Hyclone], 1% nonessen-
tial amino acids [Invitrogen], 1% OPI [Invitrogen], 100 U/ml gentamicin,
and 50  M 2-mercaptoethanol) supplemented with 10  g/ml anti-IgM
( -chain specific, F[ab]2 fragment, Jackson ImmunoResearch Laboratories)
or 5  g/ml LPS (Escherichia coli, Sigma-Aldrich). At day 3, CFSE levels were
assessed by flow cytometry using DAPI to exclude dead cells.
Construction of BM chimeras. The indicated hosts were maintained on
water containing a Bactrim suspension (400 mg sulfamethoxazole and 80
mg trimethoprim/500 ml water) for 1 wk before, and 3 wk after, lethal (900
rad) irradiation. Hosts were irradiated 1 d before retro-orbital injection of
2   106 B-lineage depleted BM cells. Depletions were performed on LD
depletion columns (Miltenyi Biotec) using BI-anti-B220 and SA micro-
beads (Miltenyi Biotec).
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